Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Monalizumab
DRUG: Cetuximab
OTHER: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]